Until recently, simplification of type 2 diabetes (T2D) treatment was regarded as a trade-off required for intensification. The fixed-ratio combination of insulin glargine/lixisenatide has provided an innovative solution to address some of the unmet needs in patients requiring treatment intensification.  

One in two people with T2D do not know that they have it

Please sign in to read more